Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential
thrombocythemia. Blood 2007;110:840-6.
Front-line therapy in polycythemia vera and essential
thrombocythemia. Blood Rev 2012; 26(5):205-211.
Development and validation of an international prognostic score of thrombosis in World Health Organization-essential
thrombocythemia (IPSET-thrombosis).
Pereira et al., "Risk factors for non-melanoma skin cancer in patients with essential
thrombocythemia and polycythemia vera," European Journal of Haematology, vol.
Efimova et al., "Changes in peripheral blood lymphocytes in polycythemia vera and essential
thrombocythemia patients treated with pegylated-interferon alpha and correlation with [JAK2.sup.V617F] allelic burden," Experimental Hematology & Oncology, vol.
Primary myelofibrosis (pmf), post polycythemia vera myelofibrosis (post-pv mf), post essential
thrombocythemia myelofibrosis (post-ET mf), blast phase pmf (pmf).
(2011) Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential
thrombocythemia: a retrospective study.
Calreticulin mutations and long-term survival in essential
thrombocythemia. Leukemia.
(1) Between 90% and 98% of patients with polycythemia vera and about 50% of patients with essential
thrombocythemia (ET) and primary myelofibrosis (PMF) harbor the JAK2V617F mutation.
It is associated with a multitude of conditions, including lymphoproliferative disorders (most common: 48%), myeloproliferative disorders (chronic granulocytic leukemia, essential
thrombocythemia, and polycythemia vera), neoplasms (Wilms tumor), immunological disorders, cardiovascular diseases, hypothyroidism, hemoglobinopathies, drugs (valproate, ciprofloxacin, and hydroxyethyl starch), and infections [1, 2, 4-7].
Essential
thrombocythemia (ET) is a clonal expansion of multipotential stem cells.